Cargando…
Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19). This global healthcare emergency marked the third occurrence of a deadly coronavirus (CoV) into the human society after entering the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746807/ https://www.ncbi.nlm.nih.gov/pubmed/33344509 http://dx.doi.org/10.3389/fmolb.2020.616341 |
_version_ | 1783624868222205952 |
---|---|
author | Cui, Wen Yang, Kailin Yang, Haitao |
author_facet | Cui, Wen Yang, Kailin Yang, Haitao |
author_sort | Cui, Wen |
collection | PubMed |
description | The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19). This global healthcare emergency marked the third occurrence of a deadly coronavirus (CoV) into the human society after entering the new millennium, which overwhelmed the worldwide healthcare system and affected the global economy. However, therapeutic options for COVID-19 are still very limited. Developing drugs targeting vital proteins in viral life cycle is a feasible approach to overcome this dilemma. Main protease (M(pro)) plays a dominant role in processing CoV-encoded polyproteins which mediate the assembly of replication-transcription machinery and is thus recognized as an ideal antiviral target. Here we summarize the recent progress in the discovery of anti-SARS-CoV-2 agents against M(pro). Combining structural study, virtual screen, and experimental screen, numerous therapeutic candidates including repurposed drugs and ab initio designed compounds have been proposed. Such collaborative effort from the scientific community would accelerate the pace of developing efficacious treatment for COVID-19. |
format | Online Article Text |
id | pubmed-7746807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77468072020-12-19 Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 Cui, Wen Yang, Kailin Yang, Haitao Front Mol Biosci Molecular Biosciences The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19). This global healthcare emergency marked the third occurrence of a deadly coronavirus (CoV) into the human society after entering the new millennium, which overwhelmed the worldwide healthcare system and affected the global economy. However, therapeutic options for COVID-19 are still very limited. Developing drugs targeting vital proteins in viral life cycle is a feasible approach to overcome this dilemma. Main protease (M(pro)) plays a dominant role in processing CoV-encoded polyproteins which mediate the assembly of replication-transcription machinery and is thus recognized as an ideal antiviral target. Here we summarize the recent progress in the discovery of anti-SARS-CoV-2 agents against M(pro). Combining structural study, virtual screen, and experimental screen, numerous therapeutic candidates including repurposed drugs and ab initio designed compounds have been proposed. Such collaborative effort from the scientific community would accelerate the pace of developing efficacious treatment for COVID-19. Frontiers Media S.A. 2020-12-04 /pmc/articles/PMC7746807/ /pubmed/33344509 http://dx.doi.org/10.3389/fmolb.2020.616341 Text en Copyright © 2020 Cui, Yang and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Cui, Wen Yang, Kailin Yang, Haitao Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 |
title | Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 |
title_full | Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 |
title_fullStr | Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 |
title_full_unstemmed | Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 |
title_short | Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 |
title_sort | recent progress in the drug development targeting sars-cov-2 main protease as treatment for covid-19 |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746807/ https://www.ncbi.nlm.nih.gov/pubmed/33344509 http://dx.doi.org/10.3389/fmolb.2020.616341 |
work_keys_str_mv | AT cuiwen recentprogressinthedrugdevelopmenttargetingsarscov2mainproteaseastreatmentforcovid19 AT yangkailin recentprogressinthedrugdevelopmenttargetingsarscov2mainproteaseastreatmentforcovid19 AT yanghaitao recentprogressinthedrugdevelopmenttargetingsarscov2mainproteaseastreatmentforcovid19 |